当前位置:
X-MOL 学术
›
J. Neurol. Neurosurg. Psychiatry
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis.
Journal of Neurology, Neurosurgery, and Psychiatry ( IF 11.0 ) Pub Date : 2020-02-06 , DOI: 10.1136/jnnp-2019-322309 Maxim De Schaepdryver 1 , Christian Lunetta 2 , Claudia Tarlarini 2 , Lorena Mosca 3 , Adriano Chio 4 , Philip Van Damme 5, 6 , Koen Poesen 7, 8
Journal of Neurology, Neurosurgery, and Psychiatry ( IF 11.0 ) Pub Date : 2020-02-06 , DOI: 10.1136/jnnp-2019-322309 Maxim De Schaepdryver 1 , Christian Lunetta 2 , Claudia Tarlarini 2 , Lorena Mosca 3 , Adriano Chio 4 , Philip Van Damme 5, 6 , Koen Poesen 7, 8
Affiliation
Amyotrophic lateral sclerosis (ALS) is a fatal disease defined by the progressive degeneration of both upper and lower motor neurons. The median survival after symptom onset is 3 to 5 years. Prognostic parameters have been identified and are associated with survival in ALS.1 2 Levels of neurofilament light chain (NfL) and C reactive protein (CRP) are both altered in serum of patients with ALS.3 4 Interestingly, these markers are linked to functional disability and survival in ALS.3 4 Prognostic protein biomarkers in blood are not taken into account yet when counselling patients with ALS. It is not clear to what extent these biomarkers contribute to predict survival in ALS. Here, we assessed the ability of serum NfL and CRP to predict survival in a multivariate survival model including eight other established prognostic parameters in ALS.2 ### Participants In total, 383 patients with ALS, diagnosed between 2009 and 2018 according to the revised El Escorial criteria (10.4% suspected ALS, 21.9% possible ALS, 48.6% probable ALS and 19.1% definite ALS), were included in this retrospective study. Patients were recruited at the NeuroMuscular Reference Center of the University Hospital in Leuven, Belgium and at the NEuroMuscular Omnicenter of the Niguarda Ca’ Granda Hospital in Milan, Italy. Blood samples were consecutively collected during the first visit, providing a wide variety of patient inclusions going from early symptomatic to second opinions. Serum was aliquoted, transported on dry ice and stored at −80°C until analysis. Assay specifications can be retrieved in the supplemental data. The FVC and the revised ALS Functional Rating Score (ALSFRS-r) were obtained at the latest within 3 months from sampling. For each survival analysis, the patients were classified into …
中文翻译:
探索了神经丝轻链和C反应蛋白作为肌萎缩性侧索硬化症生存的预测指标。
肌萎缩性侧索硬化症(ALS)是一种致命疾病,由上,下运动神经元的逐渐退化定义。症状发作后的中位生存期为3至5年。已经确定了预后参数,并与ALS的生存相关。12 ALS患者血清中神经丝轻链(NfL)和C反应蛋白(CRP)的水平均发生改变。34有趣的是,这些标志物与功能相关ALS中的残疾和生存。34在为ALS患者提供咨询服务时,尚未考虑血液中的预后蛋白质生物标志物。尚不清楚这些生物标记物在多大程度上有助于预测ALS的存活。在这里,我们评估了血清NfL和CRP在包括ALS中其他八个已建立的预后参数在内的多变量生存模型中预测生存的能力。2 ###参与者总共纳入了383例ALS患者,根据修订后的El Escorial标准在2009年至2018年之间诊断为疑似ALS(10.4%,可能的ALS为21.9%,可能的ALS为48.6%,确定的ALS为19.1%)。这项回顾性研究。患者是在比利时鲁汶大学医院的神经肌肉参考中心和意大利米兰的尼瓜达卡格兰达医院的NEuroMuscular Omnicenter招募的。在第一次就诊期间连续采集血液样本,从早期症状到第二意见就提供了各种各样的患者包裹体。将血清等分,在干冰上运输并保存在-80°C直至分析。可以在补充数据中检索测定规格。FVC和修订后的ALS功能评分(ALSFRS-r)至少在采样后3个月内获得。对于每个生存分析,将患者分为……
更新日期:2020-03-16
中文翻译:
探索了神经丝轻链和C反应蛋白作为肌萎缩性侧索硬化症生存的预测指标。
肌萎缩性侧索硬化症(ALS)是一种致命疾病,由上,下运动神经元的逐渐退化定义。症状发作后的中位生存期为3至5年。已经确定了预后参数,并与ALS的生存相关。12 ALS患者血清中神经丝轻链(NfL)和C反应蛋白(CRP)的水平均发生改变。34有趣的是,这些标志物与功能相关ALS中的残疾和生存。34在为ALS患者提供咨询服务时,尚未考虑血液中的预后蛋白质生物标志物。尚不清楚这些生物标记物在多大程度上有助于预测ALS的存活。在这里,我们评估了血清NfL和CRP在包括ALS中其他八个已建立的预后参数在内的多变量生存模型中预测生存的能力。2 ###参与者总共纳入了383例ALS患者,根据修订后的El Escorial标准在2009年至2018年之间诊断为疑似ALS(10.4%,可能的ALS为21.9%,可能的ALS为48.6%,确定的ALS为19.1%)。这项回顾性研究。患者是在比利时鲁汶大学医院的神经肌肉参考中心和意大利米兰的尼瓜达卡格兰达医院的NEuroMuscular Omnicenter招募的。在第一次就诊期间连续采集血液样本,从早期症状到第二意见就提供了各种各样的患者包裹体。将血清等分,在干冰上运输并保存在-80°C直至分析。可以在补充数据中检索测定规格。FVC和修订后的ALS功能评分(ALSFRS-r)至少在采样后3个月内获得。对于每个生存分析,将患者分为……